Prescribing information available here
Adverse event reporting information can be found at the bottom of this page
Correct inhaler use is the cornerstone of successful asthma and COPD treatment. Most patients learn to use Easyhaler® correctly in less than 5 minutes, thus also saving physicians’ valuable time.1-4
Bufomix Easyhaler Contraindications and Undesirable effects
Contraindications: Hypersensitivity to the active substances or lactose monohydrate (which contains small amounts of milk protein).
Undesirable effects:
Common (≥1/100 to < 1/10): Candida infections in the oropharynx, pneumonia (in COPD patients) headache, tremor, palpitations, mild irritation in the throat, coughing, dysphonia including hoarseness.
See SmPC for full list of adverse reactions
Date of preparation: October 2024 / EASYH-2724(1)
References
- Gálffy G, Mezei G, Nemeth G et al. Inhaler Competence and Patient Satisfaction with Easyhaler®: Results of Two Real-Life Multicentre Studies in Asthma and COPD. Drugs R D 2013 Sep;13(3):215–22.
- Tamasi L, Szilasi M, Gálffy G. Clinical Effectiveness of Budesonide/Formoterol Fumarate Easyhaler®, for Patients with Poorly Controlled Obstructive Airway Disease: a Real-World Study of Patient-Reported Outcomes. Adv Ther. 2018;35:1140–1152.
- Syk J, Vinge I, Sörberg M, et al. A multicenter, observational, prospective study of the effectiveness of switching from budesonide/formoterol Turbuhaler® to Budesonide/Formoterol Easyhaler®. Adv Ther. 2019;36(7):1756–1769.
- Gálffy G, Szilasi M, Tamási L. Effectiveness and patient satisfaction with budesonide/formoterol Easyhaler® among patients with asthma or COPD switching from previous treatment: a real-world study of patient-reported outcomes. Pulm Ther. 2019;5:165-177.
DATE OF PREPARATION: MAY 2023/EASYH-688(10)
FULL PRESCRIBING INFORMATION AVAILABLE HERE
For more information about Orion and Sustainability click here
| Adverse effects should be reported. You can report side effects directly via the Health Products Regulatory Authority (HPRA) website: www.hpra.ie or by email on medsafety@hpra.ie. Adverse effects should also be reported to Orion Pharma via ie.medicalinformation@orionpharma.com |
